Orthostatic Hypotension Drugs Market to grow with a CAGR of 8.26%
Increasing
healthcare infrastructure and a supportive regulatory environment are the major
drivers for the Global Orthostatic Hypotension Drugs Market.
According
to TechSci Research report, “Global Orthostatic Hypotension Drugs Market Industry
Size, Share, Trends, Competition, Opportunity and Forecast, 2018-2028”, Global Orthostatic Hypotension
Drugs Market has valued at USD 542.26 million in 2022 and is anticipated to
witness an impressive growth in the forecast period with a CAGR of 8.26%
through 2028. This can be due to collaborations and partnerships among leading
companies with a diverse approach to merge the expertise of individual companies
and to strengthen their position in the market.
Emerging
markets can be a driver in the global orthostatic hypotension drugs market.
Emerging markets refer to regions or countries with developing economies and
expanding healthcare infrastructures. Many emerging markets are investing in
healthcare infrastructure development, including the establishment of
hospitals, clinics, and healthcare facilities. This expansion improves access
to healthcare services, including diagnosis and treatment of conditions like
orthostatic hypotension. Rising income levels and government initiatives in
emerging markets may lead to increased healthcare spending. As a result, more
resources are allocated to medical research, drug development, and patient
care, benefiting the orthostatic hypotension drugs market. Emerging markets can
present opportunities for pharmaceutical companies to expand their presence and
market their orthostatic hypotension drugs. As healthcare systems mature, there
may be increased demand for specialized medications. Emerging markets may
become attractive locations for clinical trials of orthostatic hypotension
drugs due to a diverse patient population and lower research and development
costs. This can accelerate drug development and regulatory approvals.
Orthostatic
hypotension, commonly referred to as postural hypotension, is characterized by
lightheadedness brought on by low blood pressure. When someone rises after a
prolonged sitting, they frequently feel dizzy. It can be exacerbated by
dehydration, cardiac, endocrine, and neurological system issues. Additionally,
it has been found that older inhabitants of nursing homes are more prone to
O.H. than people who live in the community. A person's systolic blood pressure
and diastolic blood pressure both fall by at least 20 mm Hg when they have
orthostatic hypotension.
In
July 2022, the commercial introduction of premix Norepinephrine Bitartrate in
5% Dextrose Injection (norepinephrine), which has been approved by the U.S.
Food and Drug Administration (FDA), was announced by Baxter International Inc.,
a world leader in the development and distribution of sterile medications. When
an adult patient has severe, acute hypotension (low blood pressure),
norepinephrine is prescribed to increase blood pressure. Norepinephrine is used
to treat individuals with acute or emergent hypotension as well as
life-threatening hypotension that can happen during specific medical conditions
or surgical operations. The norepinephrine formulation from Baxter may be kept
in automated dispensing cabinets at the point-of-care and has a shelf life of
up to 21 months in the refrigerator or up to 90 days at room temperature in
overwrap. The VIAFLO container technology for norepinephrine, which is
exclusive to Baxter and free of DEHP, PVC, and natural rubber latex, is used.
Browse over XX market data Figures and spread through 110 Pages and an
in-depth TOC on "Orthostatic Hypotension Drugs Market”
Access
to medications can be a significant challenge in the global orthostatic
hypotension drugs market, as it is in many healthcare systems worldwide. Some
orthostatic hypotension drugs may not be widely available in all regions or
countries. Limited availability can result from factors such as regulatory
approvals, pharmaceutical company distribution decisions, and market demand. The
cost of medications, especially newer or specialized drugs, can be a barrier to
access. Patients may face financial challenges in obtaining these medications,
particularly if they are not covered by insurance or government healthcare
programs. Access to healthcare and medications can vary significantly between
urban and rural areas, as well as between high-income and low-income regions.
Patients in remote or underserved areas may face additional challenges in
obtaining medications. The availability of healthcare facilities, including
specialized clinics and medical professionals who can diagnose and manage
orthostatic hypotension, can impact access to medications. In regions with
limited healthcare infrastructure, patients may struggle to receive appropriate
care and prescriptions.
Global Orthostatic Hypotension Drugs Market segmentation
is based on
Product, Test Type, End User, Region and Company
Based on Product, Global Orthostatic Hypotension Drugs Market is segmented into Droxidopa,
Fludrocortisone, Indomethacin, Midodrine Hydrochloride, NSAIDs, Pyridostigmine.
Pyridostigmine is a medication used in
the treatment of various neuromuscular disorders, particularly those involving
impaired nerve-muscle communication. It belongs to a class of drugs called
cholinesterase inhibitors, which work by increasing the levels of a
neurotransmitter called acetylcholine in the neuromuscular junction (the point
of contact between nerve cells and muscle cells). Elevated acetylcholine levels
enhance muscle contractions and improve nerve signal transmission. Pyridostigmine is most prescribed for
myasthenia gravis, an autoimmune neuromuscular disorder characterized by muscle
weakness and fatigue. In myasthenia gravis, the immune system attacks the
acetylcholine receptors on muscle cells, leading to impaired nerve-muscle
communication. Pyridostigmine helps alleviate these symptoms by prolonging the
action of acetylcholine. Pyridostigmine
inhibits the enzyme acetylcholinesterase, which is responsible for breaking
down acetylcholine in the neuromuscular junction. By inhibiting
acetylcholinesterase, pyridostigmine increases the concentration and duration
of action of acetylcholine, enhancing muscle contraction and improving nerve
signal transmission.
Based on Region, North America dominated the Global Orthostatic
Hypotension Drugs Market. North America provides favorable market access
conditions for pharmaceutical companies, including patent protections and
intellectual property rights, which incentivize investment in research and
development. The United States has one of the highest healthcare expenditures
globally. This significant spending capacity allows for the purchase and
utilization of innovative drugs and treatments, including those for orthostatic
hypotension. The availability of health insurance coverage in North America,
especially in the United States, ensures that individuals have access to
healthcare services and medications, reducing financial barriers to treatment.
North America has active patient advocacy groups and organizations focused on
orthostatic hypotension. These groups raise awareness, provide support to
patients, and advocate for research and treatment options.
Asia-pacific region to fastest growth in
the Global Orthostatic Hypotension Drugs Market. Some countries in the
Asia-Pacific region have been increasing their healthcare expenditures and
investments in healthcare infrastructure. This improved access to healthcare
services can lead to better diagnosis and management of orthostatic
hypotension. Growing awareness among healthcare professionals and patients
about orthostatic hypotension and its treatment options can lead to earlier
diagnosis and increased demand for medications. The pharmaceutical industry in
the Asia-Pacific region has been expanding, with increased research and
development activities. This expansion may lead to the availability of a wider
range of medications for orthostatic hypotension. Changing lifestyles,
including dietary habits and levels of physical activity, can impact the
prevalence of orthostatic hypotension. These changes may contribute to an
increased need for treatment.
Some
of the major companies operating in the Global
Orthostatic Hypotension Drugs Market include:
- Mylan
N.V.
- Upsher-Smith
Laboratories, LLC
- Chelsea
Therapeutics International, Ltd (
- Amgen
Inc.
- F.
Hoffmann-La Roche Ltd
- Apotex
Inc
- Pfizer
Inc.
- Novartis
AG
- H.
Lundbeck A/S
- Amneal
Pharmaceuticals LLC
Download Free Sample Report
Customers can also request
10% free customization on this report
“Certain areas, particularly in
North America, are projected to exert significant demand for Orthostatic
Hypotension Drugs. The growth in the competitive landscape and the presence of
well-established companies in the market, committed to enhance the overall
wellbeing of people each year, are expected to contribute to a remarkable
growth of the Global Orthostatic Hypotension Drugs Market in the forecast
period," said Mr. Karan Chechi, Research Director with TechSci Research, a
research-based Global management consulting firm.
Orthostatic
Hypotension Drugs Market – Global Industry Size, Share, Trends, Opportunity,
and Forecast, 2018-2028 Segmented by Product (Droxidopa, Fludrocortisone,
Indomethacin, Midodrine
Hydrochloride, NSAIDs, Pyridostigmine), by Diagnostics Test Type (Blood Tests,
ECG, Echocardiogram, Stress Test),
by End User (Ambulatory Surgical Centers, Diagnostic Centers, Hospitals &
Clinics), by region, and Competition evaluated the future growth
potential of Global Orthostatic Hypotension Drugs Market and provides statistics
& information on market size, structure, and future market growth. The
report intends to provide innovative market intelligence and help decision
makers take sound investment decisions. Besides, the report also identifies and
analyzes the emerging trends along with essential drivers, challenges, and
opportunities in Global Orthostatic Hypotension Drugs Market.
Contact
Mr.
Ken Mathews
708
Third Avenue,
Manhattan,
NY,
New
York 10017
Tel:
+1-646-360-1656
Email: [email protected]
Website: www.techsciresearch.com